John Overdeck’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $121M | Buy |
3,621,200
+1,415,380
| +64% | +$35.2M | 0.09% | 258 |
|
|
2026
Q1 | $46.2M | Buy |
2,205,820
+1,781,771
| +420% | +$40.1M | 0.04% | 531 |
|
|
2025
Q4 | $9.75M | Buy |
424,049
+97,869
| +30% | +$3.22M | 0.01% | 1138 |
|
|
2025
Q3 | $9.81M | Sell |
326,180
-250,721
| -43% | -$7.52M | 0.01% | 970 |
|
|
2025
Q2 | $21M | Sell |
576,901
-56,251
| -9% | -$2.03M | 0.04% | 538 |
|
|
2025
Q1 | $22.9M | Buy |
633,152
+18,204
| +3% | +$757K | 0.05% | 437 |
|
|
2024
Q4 | $25.9M | Sell |
614,948
-140,735
| -19% | -$6.98M | 0.06% | 405 |
|
|
2024
Q3 | $42M | Buy |
755,683
+187,374
| +33% | +$9.54M | 0.09% | 272 |
|
|
2024
Q2 | $23.4M | Buy |
568,309
+152,995
| +37% | +$6.53M | 0.05% | 412 |
|
|
2024
Q1 | $19.4M | Buy |
415,314
+288,704
| +228% | +$13.6M | 0.05% | 450 |
|
|
2023
Q4 | $6.05M | Buy |
126,610
+87,410
| +223% | +$3.39M | 0.01% | 886 |
|
|
2023
Q3 | $1.4M | Sell |
39,200
-364,574
| -90% | -$14.4M | ﹤0.01% | 1726 |
|
|
2023
Q2 | $18.6M | Sell |
403,774
-84,582
| -17% | -$3.92M | 0.05% | 427 |
|
|
2023
Q1 | $19.6M | Buy |
488,356
+46,420
| +11% | +$1.99M | 0.06% | 384 |
|
|
2022
Q4 | $20.5M | Buy |
441,936
+186,547
| +73% | +$7.34M | 0.06% | 349 |
|
|
2022
Q3 | $10.6M | Buy |
255,389
+198,889
| +352% | +$10.2M | 0.04% | 478 |
|
|
2022
Q2 | $3.37M | Buy |
56,500
+17,600
| +45% | +$1.08M | 0.01% | 930 |
|
|
2022
Q1 | $2.83M | Buy |
+38,900
| New | +$2.71M | 0.01% | 1186 |
|
|
2021
Q4 | – | Sell |
-25,900
| Closed | -$2.34M | – | 4766 |
|
|
2021
Q3 | $2.34M | Sell |
25,900
-264,364
| -91% | -$23.9M | 0.01% | 1852 |
|
|
2021
Q2 | $27.7M | Buy |
290,264
+145,944
| +101% | +$15.2M | 0.06% | 383 |
|
|
2021
Q1 | $16.4M | Buy |
144,320
+84,008
| +139% | +$11.4M | 0.04% | 505 |
|
|
2020
Q4 | $8.35M | Buy |
60,312
+54,595
| +955% | +$6.48M | 0.02% | 670 |
|
|
2020
Q3 | $470K | Sell |
5,717
-33,837
| -86% | -$2.8M | ﹤0.01% | 2294 |
|
|
2020
Q2 | $3.09M | Buy |
+39,554
| New | +$2.62M | 0.02% | 886 |
|
|
2019
Q4 | – | Sell |
-7,759
| Closed | -$332K | – | 3929 |
|
|
2019
Q3 | $332K | Buy |
+7,759
| New | +$422K | ﹤0.01% | 2894 |
|
|
2015
Q4 | – | Sell |
-150,113
| Closed | -$14.5M | – | 2928 |
|
|
2015
Q3 | $14.5M | Buy |
150,113
+4,772
| +3% | +$546K | 0.07% | 288 |
|
|
2015
Q2 | $14.9M | Buy |
145,341
+132,520
| +1,034% | +$10.3M | 0.07% | 333 |
|
|
2015
Q1 | $796K | Buy |
+12,821
| New | +$712K | ﹤0.01% | 1716 |
|
Other funds holding RARE
RI
FCM
John Overdeck's RARE Position: Q2 2026 in Review
John Overdeck increased its Ultragenyx Pharmaceutical (RARE) stake by 64% in Q2 2026, buying an estimated $35.2M and bringing the position to 3,621,200 shares worth $121M. The position accounts for 0.09% of the portfolio, ranked #258.
John Overdeck first reported a position in RARE in Q1 2015 and has held it in 28 quarters since. 308 funds tracked by Wall St. Rank hold RARE as of Q2 2026.
- John Overdeck held 3,621,200 shares of Ultragenyx Pharmaceutical worth $121M as of Q2 2026.
- John Overdeck bought 1,415,380 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $35.2M.
- Ultragenyx Pharmaceutical made up 0.09% of John Overdeck's portfolio in Q2 2026, its #258 holding.
- John Overdeck first reported a position in Ultragenyx Pharmaceutical in Q1 2015 and has held it in 28 quarters since.
- 308 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.
Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.